

PTC THERAPEUTICS, INC.  
Form 8-K  
October 16, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 16, 2014**

**PTC THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction

of Incorporation

**001-35969**  
(Commission

File Number)

**04-3416587**  
(IRS Employer

Identification No.)

**100 Corporate Court**

**South Plainfield, NJ**  
(Address of Principal Executive Offices)

**07080**  
(Zip Code)

Registrant's telephone number, including area code: **(908) 222-7000**

Edgar Filing: PTC THERAPEUTICS, INC. - Form 8-K

**Not applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

The previously announced underwritten public offering of 3,450,000 shares of common stock of PTC Therapeutics, Inc. (the Company ), including 450,000 shares issued upon exercise by the underwriters of their option to purchase additional shares, closed on October 16, 2014. The Company expects its net proceeds from this offering to be approximately \$117.5 million, after deducting the underwriting discounts and commissions and estimated expenses payable by the Company.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PTC THERAPEUTICS, INC.

Date: October 16, 2014

By:

/s/ Shane Kovacs  
Shane Kovacs  
Chief Financial Officer